Hiroaki Ikesue
11PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Sep 18, 2023
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.Kenta Yamaoka, Kei Irie, Nobuhiro Hiramoto
|Mar 07, 2022
Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.Hiroaki Ikesue, Kenta Yamaoka, Ayako Matsumoto
|Nov 05, 2021
Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.Hiroaki Ikesue, Kohei Doi, Mayu Morimoto
|Apr 01, 2021
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.Hiroaki Ikesue, Kohei Doi, Mayu Morimoto
|Feb 02, 2021
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.Hiroaki Ikesue, Moe Mouri, Hideaki Tomita
|Oct 22, 2020
Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts.Saki Yoshida, Ayumi Fujimoto, Keizo Fukushima
Pageof 2
